Allergan (AGN) → Stock, financial statements
Advertising

Allergan

193.02 USD +0.03 (+0.02%)
May 08 🇺🇸 NYSE AGN
Dividends News
Favorites
  • AGN Ticker
  • 🇺🇸 NYSE Exchange
  • 16,900 Employees
3 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

The company is engaged in the production and development of new drugs in the field of pharmaceuticals, surgery, regeneration, hardware and biological effects. The main activity of the company is in 4 areas: medical aesthetics (plastic surgery), gastroenterology, Central nervous system and eye care.


In medical aesthetics, various types of breast implants, tissue expanders, and corrective injectables are presented. Gastroenterology produces tablets, capsules, suspensions, injections and rectal suppositories for appropriate treatment of gastric pathologies. In the field of eye care, ophthalmic solutions, creams, and ointments are produced. Preparations for the nervous system are available in the form of injections, tablets, capsules containing both activating and soothing components.

As of 2017, most of Allergan's shares are held by institutional investors (the Vanguard Group, Wellington Management Group, BlackRock, State Street Corporation, Fidelity Investments, and others).